Prime Medicine Receives New Zealand CTA Clearance for PM577a in Wilson Disease
CAMBRIDGE, Mass., June 18, 2026 Prime Medicine, Inc. announced that New Zealand’s Medicines and Medical Devices Safety Authority (Medsafe)...
Clinical Trials for New Therapy
AVITA Medical Reports First U.K. Clinical Success with RECELL GO
VALENCIA, Calif., June 18, 2026 AVITA Medical, Inc. announced positive first U.K. clinical experience with its RECELL GO® automated...
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 in IPF
LA JOLLA, Calif., June 18, 2026 GRI Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
MAIA Biotechnology Expands THIO-101 Trial with Winship Enrollment
CHICAGO, June 18, 2026 MAIA Biotechnology, Inc. announced that Winship Cancer Institute of Emory University, Georgia’s only National Cancer...
Longeveron Reports New Phase 2a Laromestrocel Alzheimer’s Data
Miami, Florida | June 18, 2026 Longeveron Inc. announced that an additional clinical data analysis from its Phase 2a...
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment
Ocala, Florida | June 18, 2026 AIM ImmunoTech Inc. announced that the final patient has received the first dose...
Cadrenal Therapeutics to Seek FDA Rare Pediatric Designation
Ponte Vedra, Florida | June 18, 2026 Cadrenal Therapeutics, Inc. announced plans to submit a request to the U.S....
LIR Shows Successful Needle-Free Delivery of GLP-1 Therapies
VANCOUVER, Canada, June 17, 2026 LIR Life Sciences Corp. announced the successful completion of its comparative preclinical animal study...
Corcept Resubmits Relacorilant NDA for Cushing’s Syndrome to FDA
REDWOOD CITY, Calif., June 17, 2026 Corcept Therapeutics Incorporated announced the resubmission of its New Drug Application (NDA) to...
Alkermes Highlights Strong Phase 2 Data for Alixorexton at SLEEP 2026
DUBLIN, June 17, 2026 Alkermes plc announced detailed positive results from the Phase 2 Vibrance-2 clinical trial evaluating alixorexton,...